令和2年度

巻頭言

令和2年度
ライフサイエンス研究所紀要発刊によせて
研究所長
伊木　雅之（公衆衛生学教室教授）

　ライフサイエンス研究所は近畿大学本部直轄の組織ですが、医学部の敷地内にあり、機器備品およびほとんどの教員、技術員が医学部共同研究施設と共有、兼任であることから、医学部の研究に寄与するところが大きな施設となっています。
　私立大学医学部や私立医科大学では、基礎的な研究に専念する医学部出身者は元来多くはありませんが、新臨床研修医制度の導入で母校の医学部に残る卒業生自体が減少し、研究を志向する若い医師も少なくなりました。残念ながら、私どものライフサイエンス研究所も研究者不足、特に若い医師の不足の影響をうけています。
　このように、人も時間も研究費も潤沢とはいえない中で、多くの質の高い研究成果が発表されたことは、誠に喜ばしいことであります。基礎系および臨床系の研究者の多大な御尽力と、それを支えている研究所の技術員の奮闘に敬意を表するとともに、引き続き、近畿大学、中でも医学部の研究の発展のために所員一同なお一層の努力をいたします。

令和2年度ライフサイエンス研究所紀要

免疫学教室　（宮澤　正顯　教授）

1. Hakata, Y. and M. Miyazawa.
   Deaminase-independent mode of antiretroviral action in human and mouseAPOBEC3 proteins.
   Microorganisms 8:1976, 2020.
2. Miyazawa, M.
   Immunopathogenesis of SARS-CoV-2-induced pneumonia: Lessons from
   influenza virus infection.
   Inflammation and Regeneration 40:39, 2020.
   
3. Ohtani, H., Y. Nozaki, T. Murakami, L. Lin, J. Shiono, and M. Miyazawa.
   An autopsy case of acute myocarditis with intriguing findings in lymph node characterized by proliferation of reactive plasmablasts.
   J. Clin. Exp.Hematopathol. 60:108-112, 2020.
4. Meira e Cruz, M., M. Miyazawa, D. Gozal.
   Putative contributions of circadian clock and sleep in the context of SARS
   CoV-2 infection.
   Eur. Resp. J. 55: 2001023, 2020.
5. 宮澤正顯.
   感染症の時代を生きる. 合理化 546:11-14, 2021.
6. 宮澤正顯.
   免疫. 解明病理学第４版（青笹克之, 加藤光保, 菅野祐幸編）, 医歯薬出版　印
   刷中, 2021.

解剖学教室　（重吉　康史　教授）

1. Ikegami K, Nakajima M, Minami Y, Nagano M, Masubuchi S, Shigeyoshi Y.
   cAMP response element induces Per1 in vivo. 　
   Biochem Biophys Res Commun. 2020 Oct 22;531(4):515-521 PMID: 32807491
2. Kanazawa Y, Nagano M, Koinuma S, Sujino M, Minami Y, Sugiyo S, Takeda I, Shigeyoshi Y.
   Basement membrane recovery process in rat soleus muscle after exercise-induced muscle injury.
   Connect Tissue Res. 2020 Jul 22:1-12　PMID: 32619127
3. Minami Y, Yoshikawa T, Nagano M, Koinuma S, Morimoto T, Fujioka A, Furukawa K, Ikegami K, Tatemizo A, Egawa K, Tamaru T, Taniguchi T, Shigeyoshi Y.
   Transgenic rats expressing dominant negative BMAL1 showed circadian clock amplitude reduction and rapid recovery from jet lag.
   Eur J Neurosci. 2021 Mar;53(6):1783-1793

ゲノム生物学教室　（西尾　和人　教授）

1. Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, Iwamoto Y,
   Kondoh C, Matsumoto K, Takahashi S, Yasui H, Sawa T, Onozawa Y, Chiba Y, Togashi Y, Fujita Y, Sakai K, Tomida S, Nishio K, Nakagawa K.
   Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 2020(Online ahead of print).
2. Honobe A, Sakai K, Togashi Y, Ohnuma T, Kawamura T, Nishio K, Inozume T.
   Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis. J Dermatol Sci 2020 (Online ahead of print).
3. Kawanaka Y, Kawakami H, Shimizu S, Yoshida T, Hayashi H, Nishio K, Satou T, Nakagawa K.
   A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood. Case Rep Oncol 2020; 13: 843-848.
   
4. Komeda Y, Sakurai T, Sakai K, Morita Y, Hashimoto A, Nagai T, Hagiwara S, Matsumura I, Nishio K, Kudo M.
   Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report. 　
   World J Clin Cases 2020; 8: 6389-6395.
5. Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.
   BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
   Pancreas 2020; 49: e101-e103.
6. Nishida N, Sakai K, Morita M, Aoki T, Takita M, Hagiwara S, Komeda Y, Takenaka M, Minami Y, Ida H, Ueshima K, Nishio K, Kudo M.
   Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.
   Liver Cancer 2020; 9: 426-439.
7. Noguchi T, Iwahashi N, Sakai K, Matsuda K, Matsukawa H, Toujima S, Nishio K, Ino K.
   Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact.
   Cancers (Basel) 2020; 12. (Online ahead of print).
8. Ohara S, Suda K, Sakai K, Nishino M, Chiba M, Shimoji M, Takemoto T, Fujino T, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.
   Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.
   Transl Lung Cancer Res 2020; 9: 1915-1923.
9. Omura S, Sato F, Park AM, Fujita M, Khadka S, Nakamura Y, Katsuki A, Nishio K, Gavins FNE, Tsunoda I.
   Bioinformatics Analysis of Gut Microbiota and CNS Transcriptome in Virus-Induced Acute Myelitis and Chronic Inflammatory Demyelination; Potential Association of Distinct Bacteria With CNS IgA Upregulation.
   Front Immunol 2020; 11: 1138.
10. Sakai H, Takeda M, Sakai K, Nishio K, Nakagawa K.
    Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.　 Mol Clin Oncol 2020; 13: 175-178.
11. Sakai K, Takahama T, Shimokawa M, Azuma K, Takeda M, Kato T, Daga H, Okamoto I, Akamatsu H, Teraoka S, Ono A, Ohira T, Yokoyama T, Yamamoto N, Nakagawa K, Nishio K.
    Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small-cell lung cancer (WJOG8815L). Mol Oncol 2020. (Online ahead of print).
12. Sakurai T, Nishiyama H, Sakai K, De Velasco MA, Nagai T, Komeda Y, Kashida H, Okada A, Kawai I, Nishio K, Ogata H, Kudo M.
    Mucosal microbiota and gene expression are associated with long-term remission after discontinuation of adalimumab in ulcerative colitis. Sci Rep 2020; 10: 19186.
13. Shimizu T, Nishio K, Sakai K, Okamoto I, Okamoto K, Takeda M, Morishita M,
    Nakagawa K.
    Phase I safety and pharmacokinetic study of YM155, a potent selective survivin
    inhibitor, in combination with erlotinib in patients with EGFR TKI refractory　advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol 2020; 86: 211-219.
14. Suda K, Murakami I, Obata K, Sakai K, Fujino T, Koga T, Ohara S, Hamada A, Soh J, Nishio K, Mitsudomi T.
    Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer 2020; 148: 100-104.
15. Suda K, Sakai K, Obata K, Ohara S, Fujino T, Koga T, Hamada A, Soh J, Nishio K, Mitsudomi T.
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
    Clin Lung Cancer 2020. (Online ahead of print).
16. Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, Tanaka K, Sato C, Hayashi H, Nonagase Y, Yonesaka K, Takegawa N, Okuno T, Yoshida T, Fumita S, Suzuki S, Haratani K, Saigoh K, Ito A, Mitsudomi T, Handa H, Fukuoka K, Nakagawa K, Nishio K.
    Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
    Oncologist 2020. (Online ahead of print).
17. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H.
    Multiplex gene-panel testing for lung cancer patients.
    Pathol Int 2020; 70: 921-931.
18. Fukui T, Sakai K, Sasaki J, Kakegawa MI, Igawa S, Mitsufuji H, Takeda M, Takahama T, Nakagawa K, Nishio K, Naoki K.
    Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. Cancer Biomark 2021. (Online ahead of print)
19. Goda K, Murao T, Handa Y, Katsumata R, Fukushima S, Nakato R, Osawa M, Ishii M, Fujita M, Handa O, Matsumoto H, Fujita Y, Nishio K, Wallace TM, Gomez-Esquivel R, Berzosa M, Wolfsen HC, Wallace MB, Umegaki E, Shiotani A. Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy. Esophagus 2021; 18: 306-314.
20. Handa O, Goda K, Handa Y, Fukushima S, Osawa M, Murao T, Matsumoto H, Umegaki E, Fujita Y, Nishio K, Shiotani A.
    PDZK1 induces resistance to apoptosis in esophageal adenocarcinoma cells. Esophagus 2021; 18: 655-662.
21. Kato R, Haratani K, Hayashi H, Sakai K, Sakai H, Kawakami H, Tanaka K, Takeda M, Yonesaka K, Nishio K, Nakagawa K.
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Br J Cancer 2021; 124: 914-924.
22. Minami H, Kiyota N, Kimbara S, Ando Y, Shimokata T, Ohtsu A, Fuse N, Kuboki Y, Shimizu T, Yamamoto N, Nishio K, Kawakami Y, Nihira SI, Sase K, Nonaka T, Takahashi H, Komori Y, Kiyohara K.
    Guidelines for clinical evaluation of anti-cancer drugs.
    Cancer Sci 2021. (Online ahead of print).
23. Miyagawa C, Takaya H, Sakai K, Nishio K, Konishi M, Minamiguchi S, Shimada T, Matsumura N.
    A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review. Oncologist 2021; 26: 356-361
24. Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K, Japanese Society of Medical O, Japan Society of Clinical O, Japanese Cancer A.
    Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 2021; 26: 233-283.
25. Sakai K, Tsuboi M, Kenmotsu H, Yamanaka T, Takahashi T, Goto K, Daga H, Ohira T, Ueno T, Aoki T, Nakagawa K, Yamazaki K, Hosomi Y, Kawaguchi K, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Okabe K, Yamamoto N, Nishio K.
    Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). Cancer Sci 2021; 112: 388-396.
26. Sakihama S, Morichika K, Saito R, Miyara M, Miyagi T, Hayashi M, Uchihara J, Tomoyose T, Ohshiro K, Nakayama S, Nakachi S, Morishima S, Sakai K, Nishio K, Masuzaki H, Fukushima T, Karube K.
    Genetic profile of adult T-cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLV-1 strains. Cancer Sci 2021; 112: 1300-1309.
27. Shimizu S, Sakai K, Chikugo T, Satou T, Shiraishi N, Mitsudomi T, Nishio K.
    Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. Oncol Lett 2021; 21: 320.
28. Watanabe S, Takeda M, Otani T, Yoshida T, Sakai K, Olek E, Rothenberg SM,
    Kherani J, French PP, Nishio K, Ito A, Nakagawa K.
    Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in
    a Patient With RET Fusion-Positive Breast Cancer.
    JCO Precis Oncol 2021; 5. (Online ahead of print).
    

臨床研究センター　（福岡　和也　教授）

【著書】

1. 福岡和也
   中皮腫（胸膜、腹膜など）.入門 腫瘍内科学（改訂第3版）, 日本臨床腫瘍学会 編集,
   南江堂, 東京, 2020: 184-186.

【原著】

1. Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, Tanaka K, Sato C, Hayashi H, Nonagase Y, Yonesaka K, Takegawa N, Okuno T, Yoshida T, Fumita S, Suzuki S, Haratani K, Saigoh K, Ito A, Mitsudomi T, Handa H, Fukuoka K, Nakagawa K, Nishio K.
   Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021 Apr;26(4):e588-e596. doi: 10.1002/onco.13639. Epub 2021 Jan 6. PMID:33325566; PMCID: PMC8018334.